Introduction
In published studies, continuous glucose monitoring (CGM) reduced glycated hemoglobin (A1C) levels in people with type 1 diabetes by 0.53% (CGM versus self-monitoring of blood glucose) and 0.6% (sensor-augmented insulinpump therapy versus multiple daily injections with selfmonitoring of blood glucose). 1, 2 Frequent sensor wear has been consistently associated with reduction in A1C, [1] [2] [3] but obstacles to frequent CGM use include concerns about accuracy and discomfort related to sensor placement. Improvements in sensor accuracy and greater flexibility in sensor placement may help promote CGM sensor use and, therefore, improve clinical outcomes. Such improvements may also help to expand reimbursement for CGM systems by insurance companies and other payers.
The NexSensor ™ subcutaneous glucose sensor has a form factor that is identical to-and can use the same insertion device and CGM receiver as-the commercially available Sof-Sensor ® (all Medtronic, Inc., Northridge, CA). Both NexSensor and Sof-Sensor are composed of a microelectrode with a thin coating of glucose oxidase beneath several layers of biocompatible membrane. The NexSensor features a number of manufacturing and sensor chemistry enhancements over the Sof-Sensor that are intended to improve operating life reliability and consistency between sensors. Current labeling for SofSensor allows for a maximum of 3 days of continuous use in the United States and 6 days in Europe. This labeling also indicates Sof-Sensor insertion only in the abdomen.
The present study was conducted to assess whether NexSensor was accurate for 6 days in the abdomen and buttocks insertion sites.
Methods

Study Conduct
This study was conducted according to Good Clinical Practices. Written informed consent was obtained from all subjects in accordance with U.S. regulations. The study was conducted at three clinical sites in the United States (Escondido and Santa Barbara, CA, and Renton, WA). The NexSensor was an investigational device at the time of the study but was not conducted under an investigational device exemption owing to its nonsignificant risk profile. This study was registered on ClinicalTrials.gov (NCT00865345).
Subjects were 18 to 75 years of age and had type 1 diabetes treated with an insulin pump or multiple daily injections of insulin for at least 3 months. Subjects wore the NexSensor on the abdomen and buttocks simultaneously. Sensors inserted at the abdomen site were connected to a real-time CGM system (Guardian ® REAL-Time System, Medtronic, Inc.), and sensors inserted on the buttocks site were connected to a CGM recorder (CGMS iPro ™ , Medtronic, Inc.).
All subjects were randomized to a single 12 h frequent blood sampling test on 1 of the 6 days of sensor use. Sensor values collected during these visits were compared to plasma glucose values drawn every 15 min and processed using a laboratory analyzer (YSI 2300 STAT Plus ™ , YSI, Inc., Yellow Springs, OH). The subjects' glucose was allowed to fall below 70 mg/dl as measured by the laboratory analyzer. At the discretion of the investigator, insulin was used to induce this value. A meal was then given. At the same meal or a subsequent meal, the subjects' glucose value was allowed to rise above 250 mg/dl, as measured by the laboratory analyzer.
Statistical Analyses
The accuracy analysis was derived from a data set of paired sensor and reference values obtained during the frequent-sampling visits. Sensor and reference values were restricted to 40-400 mg/dl to correspond to the sensor's performance range. Sensor and reference values were adjusted between 10 and 15 min later, in time to approximate the physiologic delay between interstitial fluid and blood as well as the delay between glucose and the sensor's displayed value. [4] [5] [6] Sensor values collected at the buttocks site using the retrospective professional CGM recorder were postprocessed using the calibration algorithm of the real-time CGM system used for collecting sensor values at the abdomen site.
The proportion of sensor values that were within 20% (or 20 mg/dl in the 40-80 mg/dl range) of corresponding reference values (i.e., the mean agreement rate) and corresponding 95% confidence interval (CI) were obtained by performing an analysis of variance model. Clarke error grid (CEG) analyses were conducted according to published criteria. 7 Mean absolute relative difference (ARD) and median ARD were calculated between the sensor and reference values relative to the reference value. Differences between sites in mean agreement, mean ARD, and CEG zones were compared using a repeated measures analysis of variance.
Statistical analyses were conducted using SAS 9.2 (SAS Institute, Cary, NC).
Results
Subjects
Sixty-three subjects were enrolled. Sixty-one subjects completed the study. No subjects discontinued the study owing to an adverse event. Two subjects withdrew because the subject or legal representative requested withdrawal from the study. Subjects were randomized to participate in frequent sampling on days 1, 2, and 4 (3 groups of 11 subjects each) or on days 3, 5, and 6 (3 groups of 10 subjects each). Demographic and other baseline characteristics are displayed in Table 1 .
Precision Analysis
A precision analysis compared the values derived from the abdomen and buttocks sensors using the abdomen sensor as the reference. The mean agreement rate within 20% (or 20 mg/dl in the 40-80 mg/dl range) was 72.48%.
Accuracy Performance
The mean agreement rate within 20% (or 20 mg/dl in the 40-80 mg/dl range) was 75.5% (95% CI, 69.5, 81.4) at the abdomen site and 73.8% (68.8, 78.8) at the buttocks site. The mean agreement rates were similar between sites (p = .78). The mean agreement rate was 75.6% (95% CI, 70.8, 80.4) when the sensor and reference data from both sites were combined. The overall median ARD was 12.3% at the abdomen site, 11.5% at the buttocks site, and 11.8% when sites were combined. The overall mean ARD was 17.1% at the abdomen site, 16.5% at the buttocks site, and 16.8% when sites were combined ( Table 2 ). The overall mean ARD was similar between sites (p = .54). The buttocks site had a higher absolute difference than the abdomen site in the 40-80 mg/dl range, and the abdomen site had a higher ARD than the buttocks site in the >240-400 mg/dl range. These differences between sites were not statistically significant (respectively, p = .36 and p = .16). The ARD was consistent from days 2 through 6 of sensor wear. Day 1 of sensor wear had a higher ARD than other days ( Table 3) . Tracings representative of good and poor agreement between sensor and reference glucose values are shown in Figure 1 .
Over 90% of paired sensor-reference values were in the A and B zones of the CEGs at the abdomen, buttocks, and combined sites (respectively, 93%, 94%, and 94%; Table 4 .
Safety
One adverse event was reported but was unrelated to the study device or procedures. The results of our study, which had a design similar to several previous investigations of CGM sensors, [8] [9] [10] are discussed here. The study 8 for regulatory approval of Sof-Sensor found a mean ARD of 19.7%. The mean ARD for NexSensor in our study was 16.8% using combined site data, 17.1% using abdomen site data, and 16.5% using buttocks site data. The difference in mean ARD between Sof-Sensor and NexSensor was nearly 3% in favor of the sensor used in our study. Furthermore, there was substantial consistency of ARD values from days 2 through 6 of sensor wear. Day 1 of sensor wear had higher ARD values than other days, perhaps owing to calibration issues. The sensor does not display values until after the initial calibration at 2 h; thereafter, the system must be calibrated once every 12 h.
The CEG analysis provides further details about the accuracy of NexSensor in our study. The proportion of paired values in CEG zones A+B was slightly lower in our study of NexSensor (94%, combined sites) than in the regulatory study 8 of Sof-Sensor (96.0%). Values in zone A, however, were higher in our study (71%, combined sites) than in the Sof-Sensor regulatory study (62%). In our study, CEG values of the combined sites, like ARD values, were mostly consistent when stratified by day. Our study showed that NexSensor was safe and accurate when placed in either the abdomen or buttocks site for 6 days of use. Mean agreement rates, overall ARD, and error grid A+B zone rates were statistically similar between sites. The mean agreement rate and ARD values suggest a potential advantage to the abdomen site in the hypoglycemic range and the buttocks site in the hyperglycemic range. However, the differences between sites in mean agreement rate and mean ARD were not statistically significant, and mechanical disturbances were not assessed for possible effects on accuracy. Published accuracy studies [11] [12] [13] of Sof-Sensor attached to the Guardian REAL-Time System in adult subjects do not specify which site was used. We are, therefore, reporting the first published study to investigate whether the Sof-Sensor/NexSensor form factor is safe and accurate for use in the abdomen and buttocks sites. This is an important finding because patients frequently use current sensors in locations other than those specified on the labeling.
Conclusions
The NexSensor was accurate and safe to wear for 6 days at the abdomen and buttocks sites. The improvements in accuracy shown in our study demonstrated that NexSensor is an advancement in the management of diabetes via CGM technology.
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